What happens when you stop taking finasteride

Two completely different questions hide inside this one, and they have completely different evidence behind them. What happens to your hair is settled and stated in a single sentence of the label. What happens to side effects that started on the drug is the most contested question in the subject. This page keeps them apart.

The hair question, answered by the label

The FDA-approved labelling says continued use is recommended to sustain benefit, that benefit should be re-evaluated periodically, and that withdrawal of treatment leads to reversal of effect within twelve months. There is no ambiguity and no hedging in it.

The trials show the mechanism of that sentence. Sixty-five men who took the drug for the first twelve months were switched to placebo for the next twelve; in the group the label reports for this comparison, the increase in hair count had reversed by month 24. Nothing accumulates. The drug holds a position while it is taken and stops holding it when it is not.

There is a mirror-image finding worth knowing about, because it is the closest thing to an argument for not delaying. Men who spent the first year on placebo and then switched to the drug gained hair — but ended up 56 hairs above their original baseline, where men who started on the drug at the outset were 91 hairs above theirs. The improvement relative to when treatment began was comparable; the absolute count was not, and that gap persisted through the remaining three years.

Read that as the label does: the hair lost while untreated does not come back when treatment starts. It is not a reason to take anything. It is a reason to understand that this is a long-term commitment before starting, which is the same conclusion the regrowth data points to.

The timing question nobody can answer

How fast the hair goes after stopping, and whether it ends up where it would have been without ever taking the drug, are not answered by the documents. The label gives a twelve-month window for reversal of effect and nothing more granular. Anyone offering you a month-by-month schedule of what falls out when is inventing it.

Reversal is not rebound

A persistent worry deserves addressing directly, because it circulates as fact: that stopping causes a crash worse than never having started — that the hair "owed" to the drug all falls at once.

The documents do not describe that. What the label describes is reversal of effect: the position the drug was holding stops being held, and the underlying trajectory resumes. In the trial arm that switched to placebo, the increase in hair count had reversed by month 24 — returned to where it began, not overshot below it. Nothing in the FDA labelling, the UK updates or the European review describes a rebound.

Which is not the same as a comfortable experience. Losing in a year what accumulated over several is a real thing to prepare for, and it is worth knowing before starting rather than after stopping.

What restarting does

The trials contain a partial answer. Some men who stopped were later switched back, and the label reports that a change from the drug to placebo reversed the gain, while men moved onto treatment later gained hair but from a lower base. Nothing in the documents describes restarting as less effective in itself — the deficit comes from the loss during the gap, not from a lost responsiveness.

That is as far as the evidence goes, and it is further than most pages on this subject admit. There is no published schedule for restarting, and this site gives none.

The side-effect question, which is harder

The controlled trials gave an encouraging answer. The label reports that resolution occurred in men who discontinued because of sexual adverse experiences, and in most of those who continued taking the drug. On that evidence, stopping fixes it.

The post-approval record gives a different answer. The same label lists, among reactions identified after approval, sexual dysfunction that continued after discontinuation of treatment — erectile dysfunction, libido disorders, ejaculation disorders, orgasm disorders — with the standing caveat that frequency cannot be estimated and causation cannot be established from voluntary reports.

The UK's figures sharpen the tension. Of 426 Yellow Card reports of finasteride and sexual dysfunction up to April 2024, the outcome was recorded as not recovered or not resolved in almost half. That is not an incidence — the reports are a self-selected population, and people whose symptoms resolve are less likely to file anything — but it is not a trivial observation either.

Both things are in the record, and a page that quotes only one of them is selling something. The full argument, with every source.

One case where the record does not say 'wait and see'

For fertility, the label reports something more specific: male infertility and poor seminal quality appear in the post-approval list, with normalisation or improvement of seminal quality reported after discontinuation of finasteride. That is the clearest statement of recovery anywhere in the document. Fertility and pregnancy have their own page.

If you are thinking about stopping

The regulators have published advice on exactly this and it is not the same in all circumstances, which is why it is quoted here as theirs rather than paraphrased as ours. If depression or suicidal thoughts develop, the MHRA's advice for the hair-loss tablet is to stop it immediately and contact a doctor as soon as possible; for the prostate tablet and for dutasteride, to contact a doctor as soon as possible. If any sexual dysfunction appears, contact a doctor about it. If you have harmed yourself or feel at risk of serious harm, call your local emergency number now.

Outside those circumstances, stopping a prescribed medicine is a conversation with the person who prescribed it — including the conversation about what will happen to your hair, which the label answers in that one flat sentence. The medicine in full is described on the finasteride page.